Start-Up Previews, June 2012
This Month's Profile Group, Atrial Fibrillation Agents: Better Drugs For The Arrhythmic Heart, features profiles of Acesion Pharma, ChanRx, Milestone Pharmaceuticals and Serodus. Plus these Start-Ups Across Health Care: Loma Vista Medical, Ra Pharmaceuticals and Solx.
You may also be interested in...
With the clinical literature documenting the structural failure rate of standard balloon catheters for balloon aortic valvuloplasty and transcatheter aortic valve implantation hovering between 10 and 17%, there is definitely a need for a more durable balloon to prevent puncturing or bursting. Loma Vista Medical Inc. thinks its recently launched TRUE Dilatation balloon meets the unique requirements of TAVI. It is made of high-strength bulletproof fibers (a composite of seven different materials/layers) that are more effective than any one material alone and are ideal to handle high-structural loads.
The gold standard for treating refractory glaucoma, trabeculectomy creates an artificial pathway to relieve intraocular pressure by forming an external bleb or blister under the eyelid so that aqueous humor fluid can drain from inside the eye to the bleb. Solx Inc. has developed an implantable device that improves on that method. The Solx Gold Shunt is a flat tube that detours fluid within the eye by using an existing pathway (the suprachoroidal space) that gradually shuts down as one ages. The shunt reconnects and reinvigorates this outflow pathway.
In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)